An indirect assay for fluorescent antinuclear antibodies (FANA) is commonly performed with sera from patients with systemic lupus erythematosus (SLE). When clinically indicated, it is best considered as a sensitive screening test, to be used before methods that are more specific for this disease or for the described disease subsets. Many articles have pointed out that a positive FANA assay is not to be equated with the diagnosis of SLE, and that the population contains more healthy subjects with a positive test than there are diseased. ' Nevertheless, the test has an important role, despite the occasional patient with 'ANA negative lupus', and a positive FANA assay has been included in the revised criteria for the diagnosis of SLE. (Table 2) . When the 50 sera were retested, the results were as on the initial reading except that, with the rat-liver and HEp-2 techniques, the readings were reversed for one sample each (2'%o variation). As those sera from patients with SLE gave essentially consistent results in all tests, it should not be surprising that this was also found with the WHO international reference ANA standard serum from a patient with active lupus. Thus, overall, where the result of FANA assay is of major clinical importance-that is, in the diagnosis of SLE-all the tests fare relatively well. The variation with other sera serves as a reminder that a positive FANA must not be equated with a diagnosis of SLE.
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